| HOME >> BIOLOGY >> TECHNOLOGY |
Sullivan played a vital role in Merrimack's acquisition of Hermes Biosciences and partnership with sanofi-aventis
Cambridge, MA (PRWEB) April 7, 2010 -- Merrimack Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the discovery and development of novel treatments for cancer and inflammation, today announced that William Sullivan has been promoted to Vice President of Finance.
“Bill has led Merrimack’s finance and accounting efforts and played a vital role in both our acquisition of Hermes Biosciences and the completion of our partnership with sanofi-aventis,” said Robert Mulroy, President and Chief Executive Officer of Merrimack Pharmaceuticals. “His past experience coupled with the work he has done at Merrimack gives our leadership team and Board of Directors full confidence that Bill is the right choice to successfully direct the Company’s financial strategy.”
In his new position, Sullivan, will continue to lead Merrimack’s finance department to ensure the Company is prepared for growth and future financings. In addition to his previous role, Sullivan now has full responsibility for the Company’s daily financial and legal operations.
Bill Sullivan brings broad experience to the role. He has established and managed finance departments and worked in public and private corporate accounting. He holds a Bachelor’s degree from Williams College, a Master’s degree in Business Administration (MBA) and a Master’s degree in Accounting from North
'/>"/>
| Source: PRWeb Copyright©2010 Vocus, Inc. All rights reserved |